WUXI APPTEC (02359): Hu Zhengguo resigned from his positions as Executive Director, Vice Chairman, and others.

WUXI APPTEC (02359) announced that the Vice Chairman of the Board of Directors, Hu Zhenguo, has notified the Board of Directors that he will resign in July 2025...

Zhitong FinanceMar 30 06:11 ET

Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?

① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.

cls.cnMar 27 04:08 ET

HK stocks move | CRO Concept stocks' gains widen, WUXI BIO (02269) rises over 6%. The Industry leader's revenue and profit have stabilized and rebounded in the fourth quarter.

The gains of CRO Concept stocks have expanded. As of the time of writing, VIVA BIOTECH (01873) is up 6.19%, priced at 2.06 Hong Kong dollars; WUXI BIO (02269) is up 5.92%, priced at 27.75 Hong Kong dollars; Joinn Laboratories (06127) is up 5.3%, priced at 15.9 Hong Kong dollars; WUXI APPTEC (02359) is up 5.46%, priced at 70.55 Hong Kong dollars; PHARMARON (03759) is up 5.16%, priced at 16.72 Hong Kong dollars.

Zhitong FinanceMar 27 03:43 ET

Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks

Moomoo NewsMar 27 02:40 ET

Trending Industry Today: WUXI XDC Leads Gains In Biotechnology Stocks

Moomoo NewsMar 27 02:20 ET

An Intrinsic Calculation For WuXi AppTec Co., Ltd. (SHSE:603259) Suggests It's 45% Undervalued

Simply Wall StMar 27 01:47 ET